Nautilus Biotechnology, Inc. - 8-K Filing
Nautilus Biotechnology reported $0.2M revenue in Q2 2026 and a net loss of $14.5M, with cash reserves at $129.2M as it shifts focus to proteoform applications. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $NAUT